- Home
- DRCT vs ICU Comparison
DRCT vs ICU Comparison
Compare DRCT & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DRCT | ICU |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 9.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | DRCT | ICU |
|---|---|---|
| Price | $1.00 | $2.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $330.00 | N/A |
| AVG Volume (30 Days) | ★ 270.9K | 53.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $62,288,000.00 | N/A |
| Revenue This Year | N/A | $1,043.70 |
| Revenue Next Year | $58.17 | $54.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.04 | $0.22 |
| 52 Week High | $6.04 | $2.98 |
Technical Indicators
Market Signals| Indicator | DRCT | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 40.84 | 55.54 |
| Support Level | $0.40 | $2.26 |
| Resistance Level | $1.96 | $2.73 |
| Average True Range (ATR) | 0.17 | 0.17 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 28.00 | 41.32 |
Price Performance
Historical ComparisonAbout DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.